{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:08:41Z","timestamp":1791090521942,"version":"4.1.0"},"reference-count":104,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T00:00:00Z","timestamp":1671408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Innumerable people worldwide die of cancer every year, although pharmaceutical therapy has actualized many benefits in human health. For background, anti-cancer drug development is difficult due to the multifactorial pathogenesis and complicated pathology of cancers. Cancer cells excrete hydrophobic low-molecular anti-cancer drugs by overexpressed efflux transporters such as multiple drug resistance 1 (MDR1) at the apical membrane. Mutation-driven drug resistance is also developed in cancer. Moreover, the poor distribution of drug to cancer cells is a serious problem, because patients suffer from off-target side effects. Thus, highly selective and effective drug delivery into solid cancer cells across the membrane should be established. It is known that substances (10\u2013100 nm in diameter) such as monoclonal antibodies (mAbs) (approximately 14.2 nm in diameter) or nanoparticles spontaneously gather in solid tumor stroma or parenchyma through the capillary endothelial fenestration, ranging from 200\u20132000 nm, in neovasculatures due to the enhanced permeability and retention (EPR) effect. Furthermore, cancer antigens, such as HER2, Nectin-4, or TROP2, highly selectively expressed on the surface of cancer cells act as a receptor for receptor-mediated endocytosis (RME) using mAbs against such antigens. Thus, antibody\u2013drug conjugates (ADCs) are promising anti-cancer pharmaceutical agents that fulfill accurate distribution due to the EPR effect and due to antibody\u2013antigen binding and membrane permeability owing to RME. In this review, I introduce the implementation and possibility of highly selective anti-cancer drug delivery into solid cancer cells based on the EPR effect and RME using anti-cancer antigens ADCs with payloads through suitable linkers.<\/jats:p>","DOI":"10.3390\/antib11040078","type":"journal-article","created":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T08:41:41Z","timestamp":1671439301000},"page":"78","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Delivery of Drugs into Cancer Cells Using Antibody\u2013Drug Conjugates Based on Receptor-Mediated Endocytosis and the Enhanced Permeability and Retention Effect"],"prefix":"10.3390","volume":"11","author":[{"given":"Toshihiko","family":"Tashima","sequence":"first","affiliation":[{"name":"Tashima Laboratories of Arts and Sciences, 1239-5 Toriyama-cho, Kohoku-ku, Yokohama 222-0035, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Zahavi, D., and Weiner, L. (2020). Monoclonal Antibodies in Cancer Therapy. Antibodies, 9.","DOI":"10.3390\/antib9030034"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1021\/acscentsci.6b00190","article-title":"Does nanomedicine have a delivery problem?","volume":"2","author":"Torrice","year":"2016","journal-title":"ACS Cent. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1016\/j.bmc.2015.06.022","article-title":"Intriguing possibilities and beneficial aspects of transporter-conscious drug design","volume":"23","author":"Tashima","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bmcl.2016.11.083","article-title":"Intelligent substance delivery into cells using cell-penetrating peptides","volume":"27","author":"Tashima","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1016\/j.bmcl.2018.07.012","article-title":"Effective cancer therapy based on selective drug delivery into cells across their membrane using receptor-mediated endocytosis","volume":"28","author":"Tashima","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1248\/cpb.c19-00854","article-title":"Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis","volume":"68","author":"Tashima","year":"2020","journal-title":"Chem. Pharm. Bull."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2020). Shortcut Approaches to Substance Delivery into the Brain Based on Intranasal Administration Using Nanodelivery Strategies for Insulin. Molecules, 25.","DOI":"10.3390\/molecules25215188"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2021). Delivery of Orally Administered Digestible Antibodies Using Nanoparticles. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073349"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2022). Delivery of Intravenously Administered Antibodies Targeting Alzheimer\u2019s Disease-Relevant Tau Species into the Brain Based on Receptor-Mediated Transcytosis. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020411"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2022). Brain Cancer Chemotherapy through a Delivery System across the Blood-Brain Barrier into the Brain Based on Receptor-Mediated Transcytosis Using Monoclonal Antibody Conjugates. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071597"},{"key":"ref_11","unstructured":"World Health Organization (2022, November 28). Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref_12","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"ref_13","unstructured":"Laughlin, C.D., and D\u2019Aquili, E.G. (1974). Biogenetic Structuralism, Columbia University Press."},{"key":"ref_14","first-page":"420","article-title":"Biogenetic Structuralism","volume":"49","author":"Leavy","year":"1976","journal-title":"Yale J. Biol. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cheng, J., Liang, M., Carvalho, M.F., Tigue, N., Faggioni, R., Roskos, L.K., and Vainshtein, I. (2020). Molecular Mechanism of HER2 Rapid Internalization and Redirected Trafficking Induced by Anti-HER2 Biparatopic Antibody. Antibodies, 9.","DOI":"10.3390\/antib9030049"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41598-019-57153-9","article-title":"Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation","volume":"10","author":"Jones","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/13543784.2015.991819","article-title":"Nivolumab for the treatment of cancer","volume":"24","author":"Gunturi","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_18","first-page":"e116686","article-title":"Monoclonal Antibodies (mAbs) Approved for Cancer Treatment in the 2020s","volume":"1","author":"Kozani","year":"2021","journal-title":"Trends Med. Sci."},{"key":"ref_19","unstructured":"(2022, August 03). Mylotarg European Public Assessment Report EMA\/155284\/2018. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/mylotarg-epar-public-assessment-report_en.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.14694\/EdBook_AM.2012.32.83","article-title":"Targeting CD30 in Hodgkin Lymphoma: Antibody-Drug Conjugates Make a Difference","volume":"32","author":"Diefenbach","year":"2012","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/mabs.20230","article-title":"Brentuximab vedotin","volume":"4","author":"Donk","year":"2012","journal-title":"MAbs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1073\/pnas.1717705115","article-title":"Tunable cytotoxic aptamer\u2013drug conjugates for the treatment of prostate cancer","volume":"115","author":"Kelly","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/0008-5472.CAN-15-1610","article-title":"SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm","volume":"75","author":"Hamblett","year":"2015","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: Mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.12862","article-title":"Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia","volume":"98","author":"Thota","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1182\/bloodadvances.2019000507","article-title":"Moxetumomab pasudotox for hairy cell leukemia: Preclinical development to FDA approval","volume":"3","author":"Lin","year":"2019","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.2147\/OTT.S219449","article-title":"Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data","volume":"13","author":"Sawalha","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/1060028020960402","article-title":"Enfortumab Vedotin-ejfv: A First-in-Class Anti\u2013Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma","volume":"55","author":"Halford","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_29","first-page":"103","article-title":"Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer","volume":"12","author":"Azar","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.21037\/atm-22-813","article-title":"Sacituzumab govitecan in triple-negative breast cancer","volume":"10","author":"Nonneville","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-021-00472-z","article-title":"Clinical Development of New Antibody\u2013Drug Conjugates in Breast Cancer: To Infnity and Beyond","volume":"35","author":"Tolaney","year":"2021","journal-title":"BioDrugs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","article-title":"Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan","volume":"11","author":"Goldenberg","year":"2019","journal-title":"MAbs"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab Mafodotin: First Approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"ref_34","first-page":"303","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab Vedotin: First Approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","article-title":"Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer","volume":"12","author":"Baik","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1200\/JCO.2022.40.6_suppl.087","article-title":"DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1\/2 multicenter study","volume":"40","author":"Patel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_39","first-page":"14","article-title":"Expanded precision medicine capabilities for strengthening oncology drug development at Daiichi Sankyo","volume":"7","author":"Murakami","year":"2021","journal-title":"J. Precis. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1248\/cpb.c17-00474","article-title":"Rapid Analysis of DOXIL Stability and Drug Release from DOXIL by HPLC Using a Glycidyl Methacrylate-Coated Monolithic Column","volume":"65","author":"Kimoto","year":"2017","journal-title":"Chem. Pharm. Bull."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2745\/dds.28.205","article-title":"History of the development of DOXIL","volume":"28","author":"Takahara","year":"2013","journal-title":"Drug Deliv. Syst."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"15507","DOI":"10.1038\/ncomms15507","article-title":"Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy","volume":"8","author":"Su","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.7150\/thno.57510","article-title":"Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice","volume":"11","author":"Xenaki","year":"2021","journal-title":"Theranostics"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12987-020-00226-z","article-title":"Identification and in vivo charac-terization of a brain-penetrating nano-body","volume":"17","author":"Wouters","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrm.2017.132","article-title":"Mechanisms of clathrin-mediated endocytosis","volume":"19","author":"Kaksonen","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and Function of Immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_47","first-page":"634","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious","year":"1988","journal-title":"J. Lab. Clin. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"818736","DOI":"10.3389\/fimmu.2022.818736","article-title":"Sialylation as an Important Regulator of Antibody Function","volume":"13","author":"Vattepu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","article-title":"The \u201cless-is-more\u201d in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"10","author":"Pereira","year":"2018","journal-title":"MAbs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.4049\/jimmunol.1800896","article-title":"Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies","volume":"202","author":"Bas","year":"2019","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/19420862.2018.1551044","article-title":"Influence of N-glycosylation on effector functions and thermal stability of glycoengi-neered IgG1 monoclonal antibody with homogeneous glycoforms","volume":"11","author":"Wada","year":"2019","journal-title":"MAbs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/sextrans-2014-051779","article-title":"Magic bullet: Paul Ehrlich, Salvarsan and the birth of venereology","volume":"91","author":"Gelpi","year":"2015","journal-title":"Sex. Transm. Infect."},{"key":"ref_53","first-page":"36","article-title":"Current situations and the future prospect of monoclonal antibody products","volume":"132","author":"Yamaguchi","year":"2014","journal-title":"Bull. Natl. Inst. Health Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11","DOI":"10.15406\/moji.2016.04.00120","article-title":"Monoclonal antibodies for cancer therapy approved by FDA","volume":"4","author":"Cai","year":"2016","journal-title":"MOJ Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/s41388-021-01811-8","article-title":"Antibody-based cancer therapy","volume":"40","author":"Goydel","year":"2021","journal-title":"Oncogene"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hammood, M., Craig, A.W., and Leyton, J.V. (2021). Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)\u2014A Necessity for Future ADC Research and Development. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070674"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/1574892816666210509001139","article-title":"Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment","volume":"16","author":"Edupuganti","year":"2021","journal-title":"Recent Pat. Anti Cancer Drug Discov."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Tong, J.T.W., Harris, P.W.R., Brimble, M.A., and Kavianinia, I. (2021). An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules, 26.","DOI":"10.3390\/molecules26195847"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1568-7864(02)00235-5","article-title":"Cleavage of cellular DNA by calicheamicin gamma1","volume":"2","author":"Elmroth","year":"2003","journal-title":"DNA Repair"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15330338211010117","DOI":"10.1177\/15330338211010117","article-title":"Nanobody Conjugates for Targeted Cancer Therapy and Imaging","volume":"20","author":"Kang","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Conilh, L., Fournet, G., Fourmaux, E., Murcia, A., Matera, E.-L., Joseph, B., Dumontet, C., and Viricel, W. (2021). Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030247"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1248\/yakushi.129.1341","article-title":"Intestinal Absorption and Secretion Mechanism of Carboxylate Drugs","volume":"129","author":"Itagaki","year":"2009","journal-title":"Yakugaku Zasshi"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4155\/bio-2021-0171","article-title":"Overcoming challenges associated with the bioanalysis of cysteine-conjugated metabolites in the presence of antibody\u2013drug conjugates","volume":"13","author":"Mayer","year":"2021","journal-title":"Bioanalysis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1158\/1078-0432.CCR-18-0481","article-title":"Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas","volume":"24","author":"Thompson","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1208\/s12248-010-9225-x","article-title":"Optimization of the Antitumor Activity of Sequence-specific Pyrrolobenzodiazepine Derivatives Based on their Affinity for ABC Transporters","volume":"12","author":"Kaliszczak","year":"2010","journal-title":"AAPS J."},{"key":"ref_68","unstructured":"The FDA (2022, August 01). Novel Drug Approvals for 2021, Available online: https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2021."},{"key":"ref_69","unstructured":"The FDA (2022, October 26). Novel Drug Approvals for 2022, Available online: https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2022."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.apsb.2020.04.012","article-title":"Recent advances of antibody drug conjugates for clinical applications","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/thno.7193","article-title":"Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target?","volume":"4","author":"Kobayashi","year":"2014","journal-title":"Theranostics"},{"key":"ref_73","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"ref_74","first-page":"765","article-title":"Neovasculature induced by vascular endothelial growth factor is fenestrated","volume":"57","author":"Roberts","year":"1997","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Yadav, K.S., Mishra, D.K., Deshpande, A., and Pethe, A.M. (2019). Chapter 7\u2014Levels of Drug Targeting. Basic Fundamentals of Drug Delivery, Academic Press.","DOI":"10.1016\/B978-0-12-817909-3.00007-8"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Shurbaji, S., Anlar, G.G., Hussein, E.A., Elzatahry, A., and Yalcin, H.C. (2020). Effect of Flow-Induced Shear Stress in Nanomaterial Uptake by Cells: Focus on Targeted Anti-Cancer Therapy. Cancers, 12.","DOI":"10.3390\/cancers12071916"},{"key":"ref_77","first-page":"2943","article-title":"Multifactorial determinants that govern nanoparticle uptake by human endothelial cells under flow","volume":"7","author":"Samuel","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Papademetriou, I., Vedula, E., Charest, J., and Porter, T. (2018). Effect of flow on targeting and penetration of angiopep-decorated nanoparticles in a microfluidic model blood-brain barrier. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205158"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"517","DOI":"10.4161\/19336918.2014.970001","article-title":"Flow shear stress regulates endothelial barrier function and expression of angiogenic factors in a 3D microfluidic tumor vascular model","volume":"8","author":"Buchanan","year":"2014","journal-title":"Cell Adhes. Migr."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2","DOI":"10.14532\/mvrc.6.2","article-title":"Tumor stromal barrier and cancer stromal targeting therapy","volume":"6","author":"Yasunaga","year":"2013","journal-title":"Microvasc. Rev. Commun."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0005-2736(96)00137-X","article-title":"Transport of the anti-cancer drug doxorubicin across cytoplasmic membranes and membranes composed of phospholipids derived from Escherichia coli occurs via a similar mechanism","volume":"1284","author":"Speelmans","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1530\/ERC-18-0500","article-title":"MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer","volume":"26","author":"Creemers","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.biochi.2014.07.022","article-title":"On the importance of electrostatic interactions between cell penetrating peptides and membranes: A pathway toward tumor cell selectivity?","volume":"107","author":"Jobin","year":"2014","journal-title":"Biochimie"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1096\/fj.12-216176","article-title":"Tryptophan within basic peptide sequences triggersglycosaminoglycan-dependent endocytosis","volume":"27","author":"Bechara","year":"2013","journal-title":"FASEB J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e2109210","DOI":"10.1002\/adma.202109210","article-title":"Antibody-Incorporated Nanomedicines for Cancer Therapy","volume":"34","author":"Wu","year":"2022","journal-title":"Adv. Mater."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2012.09.025","article-title":"Chemistry for peptide and protein PEGylation","volume":"64","author":"Roberts","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Adhipandito, C.F., Cheung, S.-H., Lin, Y.-H., and Wu, S.-H. (2021). Atypical Renal Clearance of Nanoparticles Larger than the Kidney Filtration Threshold. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222011182"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"17068","DOI":"10.1038\/s41598-017-17183-7","article-title":"Phagosomal transport depends strongly on phagosome size","volume":"7","author":"Keller","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3389\/fimmu.2020.01066","article-title":"Phagocytosis: Our Current Understanding of a Universal Biological Process","volume":"11","author":"Rosales","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Doshi, N., and Mitragotri, S. (2010). Macrophages recognize size and shape of their targets. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010051"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2217\/nnm.11.19","article-title":"Nanoparticle PEGylation for imaging and therapy","volume":"6","author":"Jokerst","year":"2011","journal-title":"Nanomedicine"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0169-409X(02)00026-1","article-title":"PEGylated antibodies and antibody fragments for improved therapy: A review","volume":"54","author":"Chapman","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_93","unstructured":"Springer Protocols Handbooks, Kontermann, R., and D\u00fcbel, S. (2010). PEGylation of Antibody Fragments to Improve Pharmacodynamics and Pharmacokinetics. Antibody Engineering, Springer."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1073\/pnas.95.8.4607","article-title":"Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment","volume":"95","author":"Hobbs","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"205","DOI":"10.12659\/AOT.889188","article-title":"Human albumin: Old, new, and emerging applications","volume":"18","author":"Rozga","year":"2013","journal-title":"Ann. Transplant."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Katona, G., Balogh, G.T., Darg\u00f3, G., G\u00e1sp\u00e1r, R., M\u00e1rki, \u00c1., Ducza, E., Sztojkov-Ivanov, A., T\u00f6m\u00f6si, F., Kecskem\u00e9ti, G., and Jan\u00e1ky, T. (2020). Development of Meloxicam-Human Serum Albumin Nanoparticles for Nose-to-Brain Delivery via Application of a Quality by Design Approach. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020097"},{"key":"ref_97","first-page":"47","article-title":"Disulfide linking of albumin to the hinge region of immunoglobulin G in normal human serum","volume":"749","author":"Mohammad","year":"1983","journal-title":"Biochim. Biophys. Acta BBA Protein Struct. Mol. Enzymol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1111\/j.1742-4658.2006.05341.x","article-title":"Identification and characterization of oxidized human serum albumin","volume":"273","author":"Kawakami","year":"2006","journal-title":"FEBS J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1590\/S0100-879X2009000400001","article-title":"Oxidation of the albumin thiol to sulfenic acid and its implications in the intravascular compartment","volume":"42","author":"Turell","year":"2009","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e25104","DOI":"10.1097\/MD.0000000000025104","article-title":"The evaluation of oxidative stress parameters in breast and colon cancer","volume":"100","author":"Kundaktepe","year":"2021","journal-title":"Medicine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell\u2013selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2530\/jslsm.jslsm-41_0020","article-title":"A Mechanism of Cancer Cell Cytotoxicity of Near-Infrared Photoimmunotherapy","volume":"41","author":"Sato","year":"2020","journal-title":"J. Jpn. Soc. Laser Surg. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/cdd.2013.139","article-title":"Building blocks of the apoptotic pore: How Bax and Bak are activated and oligomerize during apoptosis","volume":"21","author":"Westphal","year":"2014","journal-title":"Cell Death Differ."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-021-00666-5","article-title":"A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models","volume":"6","author":"Fan","year":"2021","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/11\/4\/78\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:44:02Z","timestamp":1760147042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/11\/4\/78"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,19]]},"references-count":104,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["antib11040078"],"URL":"https:\/\/doi.org\/10.3390\/antib11040078","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,19]]}}}